Devyser Diagnostics AB
Research Devyser Diagnostics AB (DVYSR) on Bullrun: market cap SEK 903.60M, P/E 58.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDVYSR
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 903.60M
- P/E58.2
- Financial periodQ2 2026
- RevenueSEK 60.20M
- Net incomeSEK 1.60M
- Free cash flow-SEK 2.10M
- Gross margin76.1%
Valuation Snapshot
latest market cap is SEK 903.60M; P/E is 58.2.
Peer valuation comparison
Latest P/E is 58.15x versus a Healthcare sector median of 24.61x (136.3% above).
Latest P/E is 58.15x versus a Sweden median of 18.18x (219.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 250.60M | -SEK 8.40M | n/a | 80.6% | n/a | SEK 77.50M | SEK 51.90M | SEK 354.40M |
| FY2024 | SEK 216.80M | -SEK 61.50M | n/a | 79.7% | n/a | SEK 144.50M | SEK 59.10M | SEK 349.10M |
| FY2023 | SEK 169.30M | -SEK 53.60M | n/a | 85.5% | n/a | SEK 262.90M | n/a | n/a |
| FY2022 | SEK 126.70M | -SEK 45.90M | n/a | 81.6% | n/a | SEK 363.60M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 903.60M | 58.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Devyser Diagnostics AB's market cap?
Devyser Diagnostics AB's market capitalization is SEK 903.60M.
What is Devyser Diagnostics AB's P/E ratio?
Devyser Diagnostics AB's price-to-earnings (P/E) ratio is 58.2.
What does Devyser Diagnostics AB do?
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results.